BeyondSpring is a holding company. Through its subsidiaries, Co. is principally engaged in clinical stage biopharmaceutical activities focused on the development of cancer therapies. Co.'s primary asset, Plinabulinv, a Selective Immunomodulating Microtubule-Binding Agent, is being developed as a pipeline in a drug in various cancer indications. Co. is also developing three small molecule immune agents in preclinical stages. In addition, Co.'s subsidiary, SEED Therapeutics Inc., is utilizing a certain Targeted Protein Degradation platform, or molecular glue technology, to develop therapeutic agents from internal research and development efforts and from collaboration. The BYSI average annual return since 2017 is shown above.
The Average Annual Return on the BYSI average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether BYSI average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BYSI average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|